NASDAQ: HSIC · Medical Distribution

Henry Schein (HSIC) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Henry Schein (HSIC) at $89.58 a share. The stock last closed at $84.96, which puts the model's fair value 5.4% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Henry Schein, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$89.58midpoint of 2,000 simulations
Last close$84.96NASDAQ: HSIC
Gap to fair value+5.4%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $89.58, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $84.96 is 5.4% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 23 Feb 2027. Options prices imply a move of about 8% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give HSIC?

The calibrated range for HSIC over 63 trading days is $77.11 to $94.06. It sits around the last close, and its width comes from the volatility that HSIC's own options imply (29% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $66.19 to $117.88. In 54% of the simulations the fair value came out above the price the model ran on.

$42.22$166.32
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $89.58. Dashed line: the last close, $84.96.

Faircurve Insights · 14 Nov 2026

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. It is classed under Healthcare, Medical Distribution, and Faircurve has valued it since 1 May 2026.

Faircurve's model put the fair value at $89.58 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $89.33, so the fair value moved +0.3%. The calibrated range over 63 trading days runs from $78.26 to $95.46. It is built around the price from the volatility the stock's own options imply, and is calibrated weekly against realised prices across 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade covers input completeness, the number of comparables and how closely they agree, and the width of the range. It does not say whether the fair value is right.

The model's overall quality score is 53 out of 100, a composite of six factors scored against comparable companies. Capital discipline and stability both score 88. Net buybacks are 6.8% of market value against a peer median of 2.9%, and five-year EBITDA margin downside volatility is 0.4 points against 1.8 points. The balance sheet scores 26, with net debt to EBITDA at 3.40x against a peer median of 1.17x. The model compares it with Globus Medical, Bruker, TG Therapeutics, Universal Health Services and Bio-Rad, which have fair values on the site, and with Cardinal Health, Cencora and McKesson, which have no verdict on this date.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does HSIC report earnings, and how has the stock reacted?

Henry Schein's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.

Options prices on 13 Nov 2026 imply a move of about 7.1% in either direction through the nearest expiry, about 34 days out. That is the size the market is pricing, not a direction. HSIC's 30 day implied volatility works out to about 8.5% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across HSIC's last 8 reports, ignoring direction, was 2.7%.

0%5%10%15%no quote6.6%25 Feb '25no quote1.4%5 May '25no quote5.3%5 Aug '25no quote11.4%4 Nov '25no quote1.7%24 Feb '26no quote0.6%5 May '267.2%3.6%4 Aug '266.9%1.9%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does HSIC score on business quality?

Henry Schein's overall quality score is 53 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.307.0%ROIC46.9%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).721.26xFCF / net income2.64x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.454.0%Revenue growth, trailing10.3%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.886.8%Net buybacks / market value2.9%
Balance sheetNet debt to EBITDA and interest coverage.263.40xNet debt / EBITDA1.17x
StabilityDownside volatility of the EBITDA margin over the last five years.880.4 ptsEBITDA margin downside volatility, 5y1.8 pts

How does HSIC compare with similar companies?

The companies in medical distribution closest to Henry Schein in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
CAH Cardinal Health, Inc.$283.85$288.57+1.7%Low evidence grade
COR Cencora, Inc.$356.94$377.17+5.7%Low evidence grade
MCK McKesson Corporation$1,105.04$1,118.05+1.2%Low evidence grade
GMED Globus Medical, Inc.$70.50$76.21+8.1%Fairly valued
BRKR Bruker Corporation$60.62$64.27+6.0%Fairly valued
TGTX TG Therapeutics, Inc.$62.76$75.36+20.1%Undervalued
UHS Universal Health Services, Inc.$197.80$310.03+56.7%Undervalued
BIO Bio-Rad Laboratories, Inc.$360.26$340.60-5.5%Fairly valued

What the comparable companies' multiples alone would give for HSIC, the peer-implied price, is $101.10 a share on this run. The fair value weighs that against the company's own multiple.

All healthcare stocks ranked by gap to fair value

Henry Schein at a glance

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services.

Market value
$9.5B
Sector
Healthcare
Industry
Medical Distribution
Revenue expected, next twelve months
$14.3B
Consensus revenue growth, next fiscal year
+5.0%
Analysts with estimates
10
Beta to the US market
0.51
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. HSIC was among them.

How the fair value is worked out: the model prices Henry Schein on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for HSIC was $89.33. As of 14 Nov 2026 it is $89.58, a change of +0.3%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Henry Schein's valuation

Is Henry Schein stock undervalued or overvalued?

On Faircurve's model, HSIC reads as Fairly valued as of 14 Nov 2026. The model's fair value is $89.58 a share against a last close of $84.96, a gap of +5.4%.

What is HSIC's fair value?

$89.58 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $66.19 to $117.88.

What price range does the model give HSIC?

$77.11 to $94.06 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Henry Schein report earnings next?

The next report is scheduled for 23 Feb 2027. Companies can move their dates.

How much has HSIC moved on past earnings reports?

Across its last 8 reports the median two session move was 2.7%, ignoring direction. The largest was +11.4% around the report of 4 Nov 2025.

How confident is the model in this valuation?

The model's evidence grade for HSIC is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on HSIC

The model holds no idea open on HSIC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HSIC with their outcomes. A free account is enough.

Keep reading